Free Trial

HC Wainwright Has Optimistic Outlook of TNGX Q2 Earnings

Tango Therapeutics logo with Medical background

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, June 30th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.35) per share for the quarter, up from their previous estimate of ($0.37). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.45) EPS, Q2 2026 earnings at ($0.40) EPS and Q4 2026 earnings at ($0.37) EPS.

Tango Therapeutics Price Performance

Shares of TNGX stock traded up $0.04 during trading hours on Wednesday, hitting $5.69. The stock had a trading volume of 620,177 shares, compared to its average volume of 1,585,611. The stock's 50 day moving average is $3.16 and its 200 day moving average is $2.59. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02. The firm has a market capitalization of $616.74 million, a PE ratio of -4.66 and a beta of 1.63.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). The firm had revenue of $5.39 million for the quarter, compared to analysts' expectations of $6.73 million. Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. TCG Crossover Management LLC acquired a new position in shares of Tango Therapeutics during the 4th quarter valued at about $33,174,000. Boxer Capital Management LLC purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth about $32,077,000. Gilead Sciences Inc. purchased a new stake in shares of Tango Therapeutics during the fourth quarter worth about $15,000,000. Farallon Capital Management LLC acquired a new position in Tango Therapeutics in the fourth quarter worth about $12,360,000. Finally, Balyasny Asset Management L.P. grew its stake in Tango Therapeutics by 22.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 3,279,196 shares of the company's stock worth $10,133,000 after purchasing an additional 592,000 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company's stock.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Further Reading

Earnings History and Estimates for Tango Therapeutics (NASDAQ:TNGX)

Should You Invest $1,000 in Tango Therapeutics Right Now?

Before you consider Tango Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.

While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines